Search results for "Oncolytic virus"

showing 9 items of 39 documents

Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of …

2013

Bernd Heinrich,* Katrin Goepfert,* Maike Delic, Peter R Galle, Markus MoehlerUniversity Medical Center of the Johannes Gutenberg University Mainz, 1st Department of Internal Medicine, Langenbeckstrasse, Mainz, Germany *These authors contributed equally to this workIntroduction: Tumor-directed and immune-system-stimulating therapies are of special interest in cancer treatment. Here, we demonstrate the potential of parvovirus H-1 (H-1PV) to efficiently kill colorectal cancer cells and induce immunogenicity of colorectal tumors by inducing maturation of dendritic cells (DCs) alone and also in combination with cytostatic drugs in vitro. Using our cell culture model, we have additionally investi…

Parvovirus H-1business.industrymedicine.medical_treatmentOncoTargets and TherapyOncolytic virusImmune systemCytokineOncologyAntigenCTLA-4ImmunologyCancer researchmedicineSW480Cytotoxic T cellPharmacology (medical)dendritic cellsbusinessTremelimumabmedicine.drugOriginal ResearchOncoTargets and Therapy
researchProduct

Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach

2013

Orthotopic bladder cancer xenografts are essential for testing novel therapies and molecular manipulations of cell lines in vivo. Current xenografts rely on tumor cell inoculation by intravesical instillation or direct injection into the bladder wall. Instillation is limited by the lack of cell lines that are tumorigenic when delivered in this manner. The invasive model inflicts morbidity on the mice by the need for laparotomy and mobilization of the bladder. Furthermore this procedure is complex and time-consuming. Three bladder cancer cell lines (UM-UC1, UM-UC3, UM-UC13) were inoculated into 50 athymic nude mice by percutaneous injection under ultrasound guidance. PBS was first injected b…

PathologyMouseTumor PhysiologyCancer Treatmentlcsh:MedicineMiceBasic Cancer ResearchMedicineUltrasonicslcsh:ScienceBladder Cancer and Urothelial Neoplasias of the Urinary TractMultidisciplinaryUltrasoundAnimal ModelsBladder CancerOncolytic VirusesOncologySurgery Computer-AssistedMedicineOncology AgentsFemaleImmunotherapyResearch Articlemedicine.drugmedicine.medical_specialtyClinical Research DesignUrologyTransplantation HeterologousModel OrganismsIn vivoCell Line TumorAnimalsHumansBioluminescence imagingddc:610Animal Models of DiseaseBiologyCell ProliferationCisplatinBladder cancerbusiness.industrylcsh:RCancers and NeoplasmsChemotherapy and Drug Treatmentmedicine.diseaseGemcitabineOncolytic virusTransplantationGenitourinary Tract TumorsUrinary Bladder NeoplasmsFeasibility Studieslcsh:QbusinessPLoS ONE
researchProduct

Antitumour activity of mononuclear phagocytes: role of tumour necrosis factor alpha.

1992

Tumour necrosis factor alpha (TNF) is a cytokine produced by mononuclear phagocytes (MP) originally discovered for its cytotoxic activity on tumour cell targets. It was subsequently demonstrated that, in addition to its oncolytic potential, TNF exerts a wide variety of activities on the host defensive system against malignancies. This article briefly reviews the current concepts on the role of TNF in the antitumour activity of MP.

Pulmonary and Respiratory MedicineCytotoxicity ImmunologicPhagocytesbusiness.industryTumor Necrosis Factor-alphamedicine.medical_treatmentCellTumour necrosis factor alphaOncolytic virusKiller Cells NaturalMajor Histocompatibility ComplexCytokinemedicine.anatomical_structureNeoplasmsImmunologymedicineCytotoxic T cellHumansTumor necrosis factor alphabusinessRespiration; international review of thoracic diseases
researchProduct

Evolution of oncolytic viruses.

2015

Owing to their replicative capacity, oncolytic viruses (OVs) can evolve under the action of natural selection. Reversion to virulence and recombination with wild-type strains may compromise OV safety, therefore requiring evolutionary risk assessment studies. On the other hand, evolution can be directed in the laboratory to create more potent and safer OVs. Previous work in the experimental evolution field provides a background for OV directed evolution, and has identified interesting exploitable features. While genetic engineering has greatly advanced the field of oncolytic virotherapy, this approach is sometimes curtailed by the complexity and diversity of virus-host interactions. Directed…

Replicative capacityGeneticsOncolytic VirotherapyExperimental evolutionNatural selectionExtramuralNeoplasms therapyComputational biologyBiologyDirected evolutionOncolytic virusEvolution MolecularOncolytic VirusesVirologyNeoplasmsAnimalsHumansCurrent opinion in virology
researchProduct

Parvovirus H-1-Induced Tumor Cell Death Enhances Human Immune Response In Vitro via Increased Phagocytosis, Maturation, and Cross-Presentation by Den…

2005

Oncotropic and oncolytic viruses have attracted high attention as antitumor agents because they preferentially kill cancer cells in vitro and reduce the incidence of spontaneous, induced, or implanted animal tumors. Some autonomous parvoviruses (H-1, minute virus of mice) and derived recombinant vectors are currently under preclinical evaluation. Still not fully understood, their antitumor properties involve more than just tumor cell killing. Because wild-type parvovirus-mediated tumor cell lysates (TCLs) may trigger antigen-presenting cells (APCs) to augment the host immune repertoire, we analyzed phagocytosis, maturation, and crosspresentation of H-1-induced TCLs by human dendritic cells …

Skin NeoplasmsParvovirus H-1ApoptosisBiologyParvovirusMiceImmune systemCross-PrimingAntigenPhagocytosisAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedGeneticsCytotoxic T cellAnimalsHumansMelanomaMolecular BiologyCryopreservationCross-presentationCell DifferentiationDendritic cellDendritic CellsOncolytic virusCancer cellImmunologyCancer researchMolecular MedicineT-Lymphocytes CytotoxicHuman Gene Therapy
researchProduct

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

2022

Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short …

immune checkpoints inhibitionCancer ResearchOncologyoncolytic virusesMini ReviewcancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensimmunotherapyCAR-T therapyCRISPR/Cas9RC254-282Frontiers in Oncology
researchProduct

Classification of current anticancer immunotherapies.

2014

© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

immunostimulatory cytokinesmedicine.medical_treatmentReviewBioinformaticsDNA-based vaccinesEfficacy0302 clinical medicineCancer immunotherapyNeoplasmspeptide-based vaccines0303 health sciencesPatología//purl.org/becyt/ford/3.1 [https]CANCER3. Good healthMedicina BásicaOncologycheckpoint blockers030220 oncology & carcinogenesisQR180//purl.org/becyt/ford/3 [https]ImmunotherapyCIENCIAS MÉDICAS Y DE LA SALUDmedicine.drug_classInmunologíaadoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonistsMonoclonal antibodydendritic cell-based interventionsToll-like receptor agonistsRC025403 medical and health sciencesImmune systemAntigen[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologyadoptive cell transfer030304 developmental biologyIMMUNOTHERAPIESbusiness.industryCancerImmunotherapymedicine.diseaseR1Oncolytic virusoncolytic virusesImmunologybusinessOncotarget
researchProduct

Mechanisms of cell death in canine parvovirus-infected cells provide intuitive insights to developing nanotools for medicine

2010

Jonna Nykky, Jenni E Tuusa, Sanna Kirjavainen, Matti Vuento, Leona GilbertNanoscience Center and Department of Biological and Environmental Science, University of Jyväskylä, FinlandAbstract: Viruses have great potential as nanotools in medicine for gene transfer, targeted gene delivery, and oncolytic cancer virotherapy. Here we have studied cell death mechanisms of canine parvovirus (CPV) to increase the knowledge on the CPV life cycle in order to facilitate the development of better parvovirus vectors. Morphological studies of CPV-infected Norden laboratory feline kidney (NLFK) cells and canine fibroma cells (A72) displayed characteristic apoptotic events. Apoptosis was f…

nekroosianimal diseasesvirusesGene ExpressionPharmaceutical ScienceApoptosisViral Nonstructural Proteinsnecrosis0302 clinical medicineInternational Journal of NanomedicineDrug DiscoveryCaspaseOriginal ResearchMembrane Potential MitochondrialOncolytic Virotherapy0303 health sciencesCell DeathbiologynanoparticleCell Cycleapoptosiscanine parvovirusCanine parvovirusGeneral MedicineFlow Cytometry3. Good healthNanomedicineCaspases030220 oncology & carcinogenesisvirotherapyProgrammed cell deathParvovirus CaninenanopartikkeliBiophysicsBioengineeringDNA FragmentationGene deliveryCell LineBiomaterials03 medical and health sciencesDogsMicroscopy Electron TransmissionAnimalsHumansVirotherapyapoptoosi030304 developmental biologyParvovirusOrganic Chemistrybiology.organism_classificationVirologyOncolytic viruskoiran parvovirusviroterapiaMicroscopy FluorescenceApoptosisCatsbiology.proteinDNA DamageHeLa CellsInternational Journal of Nanomedicine
researchProduct

Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus

2010

Apoptosis is a fundamental host defence mechanism against invading microbes. Inactivation of NF-kappaB attenuates encephalomyocarditis virus (EMCV) virulence by triggering rapid apoptosis of infected cells, thereby pre-emptively limiting viral replication. Recent evidence has shown that hypoxia-inducible factor (HIF) increases NF-kappaB-mediated anti-apoptotic response in clear-cell renal cell carcinoma (CCRCC) that commonly exhibit hyperactivation of HIF due to the loss of its principal negative regulator, von Hippel-Lindau (VHL) tumour suppressor protein. Here, we show that EMCV challenge induces a strong NF-kappaB-dependent gene expression profile concomitant with a lack of interferon-me…

virusesTransplantation HeterologousApoptosisMice SCIDBiologyNF-κBMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRNA interferenceCell Line TumorVHLEMCVBasic Helix-Loop-Helix Transcription FactorsAnimalsHIFEncephalomyocarditis virusRNA Small InterferingCarcinoma Renal CellResearch Articles030304 developmental biology0303 health sciencesNF-kappa BNF-κBNFKB1RCCVirologyKidney Neoplasms3. Good healthOncolytic virusOncolytic VirusesViral replicationchemistryVon Hippel-Lindau Tumor Suppressor ProteinApoptosisCell culture030220 oncology & carcinogenesisCancer researchMolecular MedicineRNA InterferenceSignal transductionSignal TransductionEMBO Molecular Medicine
researchProduct